WebAug 1, 2024 · The result of CheckMate 9DW is eagerly awaited and a positive result may support the role of combining anti-CTLA4 and anti-PD-1/PD-L1 blockade as one of the … WebDec 13, 2024 · The phase 1–2 CheckMate 040 trial appears to be the first to report the use of a PD-1 inhibitor (in this case nivolumab) in patients with advanced hepatocellular carcinoma, most of whom had received previous sorafenib therapy. The results of CheckMate 040 cohorts 1 and 2 showed that nivolumab monotherapy had a clinical benefit.
Nivolumab-ipilimumab combo has ‘robust’ clinical benefit
WebMar 18, 2024 · However, the continued approval of the Opdivo-Yervoy combo treatment for HCC relies on the confirmation of clinical benefits in Phase 3 clinical trials. One such study is the CheckMate 9DW trial (NCT04039607), currently recruiting participants worldwide. WebJul 26, 2024 · The Opdivo and Yervoy combination won accelerated approval with the FDA in March 2024. The recent voluntary withdrawal of the Opdivo monotherapy indication … the ordnance unity centre for health enfield
National Center for Biotechnology Information
WebAug 7, 2012 · An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Web14 hours ago · CheckMate is a weekly newsletter from RMIT FactLab recapping the latest in the world of fact checking and misinformation. It draws on the work of FactLab's … WebAug 13, 2024 · The 60-month OS rate was 29% (95% CI, 14%-43%). In those who were given nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg … micromatic draft tower